Research graph
References from Long-Term Humoral Immune Dynamics in Healthcare Workers with Hybrid and Vaccine-Induced Immunity: The VaCoMRI Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: Paradigm for diagnostics of emerging SARS-CoV-2 variants
10.1007/s00430-022-00728-7 · 2022 · External reference
Effectiveness of COVID-19 Vaccines over a 9-Month Period in North Carolina
10.1056/nejmoa2117128 · 2022 · External reference
10.3389/fimmu.2022.1035441
10.3389/fimmu.2022.1035441 · External reference
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
10.1016/j.immuni.2024.01.017 · 2024 · External reference
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
10.1016/j.diagmicrobio.2022.115659 · 2022 · External reference
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
10.1038/s41467-021-27649-y · 2022 · External reference
Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany
10.3201/eid2803.204436 · 2022 · External reference
Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection
10.1056/nejmoa2118691 · 2022 · External reference
Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses
10.1038/s41598-024-55245-9 · 2024 · External reference
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial
10.1016/s0140-6736(21)02717-3 · 2021 · External reference
Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
10.1056/nejmoa2027906 · 2020 · External reference
Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months
10.1056/nejmoa2114583 · 2021 · External reference
10.21203/rs.3.rs-862966/v1
10.21203/rs.3.rs-862966/v1 · External reference
Efficacy of a Fourth Dose of COVID-19 mRNA Vaccine against Omicron
10.1056/nejmc2202542 · 2022 · External reference
A Bivalent Omicron-Containing Booster Vaccine against COVID-19
10.1056/nejmoa2208343 · 2022 · External reference
Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: Paradigm for diagnostics of emerging SARS-CoV-2 variants
10.1007/s00430-022-00728-7 · ExternalCitation · doi-reference
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
10.1016/j.diagmicrobio.2022.115659 · ExternalCitation · doi-reference
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
10.1016/j.immuni.2024.01.017 · ExternalCitation · doi-reference
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial
10.1016/s0140-6736(21)02717-3 · ExternalCitation · doi-reference
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
10.1038/s41467-021-27649-y · ExternalCitation · doi-reference
Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses
10.1038/s41598-024-55245-9 · ExternalCitation · doi-reference
Efficacy of a Fourth Dose of COVID-19 mRNA Vaccine against Omicron
10.1056/nejmc2202542 · ExternalCitation · doi-reference
Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
10.1056/nejmoa2027906 · ExternalCitation · doi-reference
Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months
10.1056/nejmoa2114583 · ExternalCitation · doi-reference
Effectiveness of COVID-19 Vaccines over a 9-Month Period in North Carolina
10.1056/nejmoa2117128 · ExternalCitation · doi-reference
Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection
10.1056/nejmoa2118691 · ExternalCitation · doi-reference
A Bivalent Omicron-Containing Booster Vaccine against COVID-19
10.1056/nejmoa2208343 · ExternalCitation · doi-reference
10.21203/rs.3.rs-862966/v1
10.21203/rs.3.rs-862966/v1 · ExternalCitation · doi-reference
Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany
10.3201/eid2803.204436 · ExternalCitation · doi-reference
10.3389/fimmu.2022.1035441
10.3389/fimmu.2022.1035441 · ExternalCitation · doi-reference
